Existing holders have the offer of buying a convertible note for 1$. The lead manager gets the same because it will cost them 1$ (or 11M dollars if you look at it that way).
As far at the options go.... 1:5 is a ratio of how many options they get per convertible note they buy.
STK (the lead broker) is putting 20M into this raise (they have good terms, yes). 25M is coming from the existing directors. Pretty strong show of confidence i'd say. They are hoping to get another 15M from existing shareholders (for example I will be supporting this) but if they do not, the shortfall can be picked up by either of the above, and failing that, can be drawn down as a government loan against R&D.
Funding to commercialization now looks extremely positive, and this was always the goal prior to any sort of IPO or trade sale. Yes it has taken onger than hoped, but a new and streamlined company with experienced directors who have strongly led companies at this stage of the game are on board to get the job done.
Lets build this Sydney Plant and start making 95% margins on the covimmune (and subsequent other hyperimmune product.
